{
    "nctId": "NCT01138046",
    "briefTitle": "Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC",
    "officialTitle": "An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Number of Participants With Intolerable Toxicities in Phase I of the Study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Prior written consent in participating in the study by the subject or his/her private attorney.\n* Japanese female \\>=18 years of age.\n* Invasive breast cancer with stage IV disease.\n* Documentation by local laboratory of ErbB2 status by immunohistochemistry (IHC) or amplification by fluorescence in situ hybridization (FISH).\n* If a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred \\>12 months after completion of this treatment and the patients recovered from all associated toxicities.\n* Measurable lesion(s) according to RECIST criteria.\n* Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigational treatment.\n* For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:\n\n  * Patient with visceral disease that requires chemotherapy (e.g., patients with liver or lung metastases).\n  * Rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy, as determined by the investigator.\n  * Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment.\n  * Subjects recovered from all the associated toxicities by prior endocrine therapy.\n* Eastern cooperative oncology group (ECOG) Performance status (PS) of 0 or 1.\n* Able to swallow and retain oral medication.\n* Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Pregnant or lactating females at anytime during the study.\n* Received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic disease.\n* History of other malignancy.\n* Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab, in the adjuvant setting.\n* Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment.\n* Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.\n* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.\n* Uncontrolled infection.\n* Patients having at least positive antibody either to HBs or HBc.\n* Patients who have had a positive HCV antibody.\n* Peripheral neuropathy grade 2 or greater.\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.\n* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.\n* Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.\n* Concurrent treatment with prohibited medications.\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.\n* Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}